Why don't we have a task force assigned to review repurposed drugs for treating COVID-19?

Dr. Kory shares that in the last 9 months, the FLCCC has been reviewing all of the literature.

‘We are some of the most highly published physicians in our specialty and the world. We have done nothing but try to figure out, how to identify a repurposed and available drug to treat this illness (Coronavirus). I am severely troubled that the NIH, the FDA, nor CDC, I do not know of any task force that was assigned or compiled assembled to review repurposed drugs in an attempt to treat this disease. Everything has been about novel or expensive pharmaceutical drugs. Our group has filled that void.’

‘A Guide to Home-based COVID treatment’ here:
http://www.CovidPatientGuide.com

Who is Dr. Kory?
Dr. Kory is a lung and ICU specialist who currently serves as the President and Chief Medical Officer of the Front Line COVID-19 Critical Care Alliance. Considered one of the world’s clinical experts on ivermectin and COVID-19, he has co-authored ten manuscripts during the pandemic to date.

On December 8, 2020, Dr. Kory testified to the US Senate Committee on Homeland Security & Governmental Affairs on the urgency and importance of expediting the federal government review of low cost, widely available and potentially beneficial early combination treatments for COVID-19. Previously, Dr. Kory had testified May 6th, 2020 to Senate Committee regarding the timely role of corticosteroids in the treatment of COVID. Prior to COVID, Dr. Kory was considered a pioneer and international expert in both therapeutic hypothermia and critical care ultrasound. He served as the senior editor of a best-selling and award-winning ultrasound textbook which is now in its 2nd edition and seventh language translation. Dr. Kory is also considered a master educator and has won major Departmental Teaching Awards at multiple institutions in his career.